Evidence map›Paper›PMID 42074618›Full record

ArticleJournal of clinical medicine2026

Survival Outcomes After irAE-Related Nivolumab Discontinuation in mNSCLC: A Multicenter Study.

Aysegul Merc Cetinkaya, Mehmet Haluk Yucel, Latif Karahan, Mustafa Ersoy, Ahmet Bilici, Mustafa Erman, Ali Murat Tatli, Sema Sezgin Goksu

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aysegul Merc CetinkayaDepartment of Medical Oncology, Akdeniz University Faculty of Medicine Hospital, Antalya 07070, Turkey.ORCID 0000-0003-2727-7387
Mehmet Haluk YucelDepartment of Medical Oncology, Medipol University Faculty of Medicine Hospital, Istanbul 34214, Turkey.ORCID 0000-0001-6880-7204
Latif KarahanDepartment of Medical Oncology, Hacettepe University Institute of Oncology, Ankara 06230, Turkey.ORCID 0000-0002-3465-1085
Mustafa ErsoyDepartment of Medical Oncology, Kutahya Health Sciences University Faculty of Medicine Hospital, Kutahya 43100, Turkey.ORCID 0000-0001-9035-4846
Ahmet BiliciDepartment of Medical Oncology, Medipol University Faculty of Medicine Hospital, Istanbul 34214, Turkey.ORCID 0000-0002-0443-6966
Mustafa ErmanDepartment of Medical Oncology, Hacettepe University Institute of Oncology, Ankara 06230, Turkey.
Ali Murat TatliDepartment of Medical Oncology, Memorial Hospital, Antalya 07025, Turkey.
Sema Sezgin GoksuDepartment of Medical Oncology, Akdeniz University Faculty of Medicine Hospital, Antalya 07070, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immune-related adverse eventsnivolumabnon-small cell lung canceroverall survivalprogression-free survivalreal-world data

Identifiers

PMID42074618
PMCPMC13115806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.